Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats

References

• Agu RU, Valiveti S, Earles DC, Klausner M, Hayden PJ, Wermeling DP, Stinchcomb AL. (2004). Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats. Endocr Res, 30, 455–467.
   PubMed Web of Science ®Google Scholar
• Agu RU, Valiveti S, Paudel KS, Klausner M, Hayden PJ, Stinchcomb AL. (2006). Permeation of WIN 55,212-2, a potent cannabinoid receptor agonist, across human tracheo-bronchial tissue in vitro and rat nasal epithelium in vivo. J Pharm Pharmacol, 58, 1459–1465.
   PubMed Web of Science ®Google Scholar
• Babu RJ, Dayal P, Singh M. (2008). Effect of cyclodextrins on the complexation and nasal permeation of melatonin. Drug Deliv, 15, 381–388.
   PubMed Web of Science ®Google Scholar
• Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W. (2004). Intranasal insulin improves memory in humans. Psychoneuroendocrinology, 29, 1326–1334.
   PubMed Web of Science ®Google Scholar
• Benedict C, Hallschmid M, Schmitz K, Schultes B, Ratter F, Fehm HL, Born J, Kern W. (2007). Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology, 32, 239–243.
   PubMed Web of Science ®Google Scholar
• Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. (2002). Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci, 5, 514–516.
   PubMed Web of Science ®Google Scholar
• Cardinali DP, Vacas MI, Boyer EE. (1979). Specific binding of melatonin in bovine brain. Endocrinology, 105, 437–441.
   PubMed Web of Science ®Google Scholar
• Charlton ST, Davis SS, Illum L. (2007). Evaluation of bioadhesive polymers as delivery systems for nose to brain delivery: in vitro characterisation studies. J Control Release, 118, 225–234.
   PubMed Web of Science ®Google Scholar
• Chow HH, Anavy N, Villalobos A. (2001). Direct nose-brain transport of benzoylecgonine following intranasal administration in rats. J Pharm Sci, 90, 1729–1735.
   PubMed Web of Science ®Google Scholar
• Christrup LL. (1997). Morphine metabolites. Acta Anaesthesiol Scand, 41, 116–122.
   PubMed Web of Science ®Google Scholar
• Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. (2007). Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm, 337, 1–24.
   PubMed Web of Science ®Google Scholar
• Dahlin M, Bergman U, Jansson B, Björk E, Brittebo E. (2000). Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm Res, 17, 737–742.
   PubMed Web of Science ®Google Scholar
• Dayal P, Shaik MS, Singh M. (2004). Evaluation of different parameters that affect droplet-size distribution from nasal sprays using the Malvern Spraytec. J Pharm Sci, 93, 1725–1742.
   PubMed Web of Science ®Google Scholar
• de Lange EC, de Boer BA, Breimer DD. 1999. Microdialysis for pharmacokinetic analysis of drug transport to the brain. Adv Drug Deliv Rev, 36, 211–227.
   PubMed Web of Science ®Google Scholar
• DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS Jr. (2000). The absolute bioavailability of oral melatonin. J Clin Pharmacol, 40, 781–784.
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH 2nd. (2010). Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci, 99, 1654–1673.
   PubMed Web of Science ®Google Scholar
• Dubey V, Mishra D, Jain NK. (2007). Melatonin loaded ethanolic liposomes: physicochemical characterization and enhanced transdermal delivery. Eur J Pharm Biopharm, 67, 398–405.
   PubMed Web of Science ®Google Scholar
• Fischer TW, Scholz G, Knöll B, Hipler UC, Elsner P. (2001). Melatonin reduces UV-induced reactive oxygen species in a dose-dependent manner in IL-3-stimulated leukocytes. J Pineal Res, 31, 39–45.
   PubMed Web of Science ®Google Scholar
• Frey I, William H. (2001). Method for Administering Insulin to the Brain. US patent application, US Patent 6313093.
   Google Scholar
• Frey WH. (2002). Bypassing the blood-brain barrier to delivery therapeutic agents to the brain and spinal cord. Drug Del Tech 2, 46–49.
   Google Scholar
• Graff CL, Pollack GM. (2005). Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci, 94, 1187–1195.
   PubMed Web of Science ®Google Scholar
• Graumlich JF, McLaughlin RG, Birkhahn D, Shah N, Burk A, Jobe PC, Dailey JW. (2000). Subcutaneous microdialysis in rats correlates with carbamazepine concentrations in plasma and brain. Epilepsy Res, 40, 25–32.
   PubMed Web of Science ®Google Scholar
• Gross EA, Swenberg JA, Fields S, Popp JA. (1982). Comparative morphometry of the nasal cavity in rats and mice. J Anat, 135, 83–88.
   PubMed Web of Science ®Google Scholar
• Hafner A, Lovric J, Voinovich D, Filipovic-Grcic J. (2009). Melatonin-loaded lecithin/chitosan nanoparticles: physicochemical characterisation and permeability through Caco-2 cell monolayers. Int J Pharm, 381, 205–213.
   PubMed Web of Science ®Google Scholar
• Hanson LR, Frey WH 2nd. (2008). Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci, 9 Suppl 3, S5.
   PubMed Web of Science ®Google Scholar
• Harris AS, Ohlin M, Lethagen S, Nilsson IM. (1988a). Effects of concentration and volume on nasal bioavailability and biological response to desmopressin. J Pharm Sci, 77, 337–339.
   PubMed Web of Science ®Google Scholar
• Harris AS, Svensson E, Wagner ZG, Lethagen S, Nilsson IM. (1988b). Effect of viscosity on particle size, deposition, and clearance of nasal delivery systems containing desmopressin. J Pharm Sci, 77, 405–408.
   PubMed Web of Science ®Google Scholar
• Hayter CL, Bishop GM, Robinson SR. (2004). Pharmacological but not physiological concentrations of melatonin reduce iron-induced neuronal death in rat cerebral cortex. Neurosci Lett, 362, 182–184.
   PubMed Web of Science ®Google Scholar
• Illum L. (2003). Nasal drug delivery–possibilities, problems and solutions. J Control Release, 87, 187–198.
   PubMed Web of Science ®Google Scholar
• Jain R, Nabar S, Dandekar P, Patravale V. (2010). Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy. Pharm Res, 27, 655–664.
   PubMed Web of Science ®Google Scholar
• Johnson NJ, Hanson LR, Frey WH. (2010). Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. Mol Pharm, 7, 884–893.
   PubMed Web of Science ®Google Scholar
• Kanikkannan N, Andega S, Burton S, Babu RJ, Singh M. (2004). Formulation and in vitro evaluation of transdermal patches of melatonin. Drug Dev Ind Pharm, 30, 205–212.
   PubMed Web of Science ®Google Scholar
• Kararli TT, Needham TE, Schoenhard G, Baron DA, Schmidt RE, Katz B, Belonio B. (1992). Enhancement of nasal delivery of a renin inhibitor in the rat using emulsion formulations. Pharm Res, 9, 1024–1028.
   PubMed Web of Science ®Google Scholar
• Kaur C, Sivakumar V, Ling EA. (2008). Melatonin and its therapeutic potential in neuroprotection. Cent Nerv Syst Agents Med Chem, 8, 260–266.
   Google Scholar
• Kreilgaard M. (2002). Assessment of cutaneous drug delivery using microdialysis. Adv Drug Deliv Rev, 54 Suppl 1, S99–121.
   PubMed Web of Science ®Google Scholar
• Lane EA, Moss HB. (1985). Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol Metab, 61, 1214–1216.
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Newsome DA. (1986). Different types of melatonin circadian secretary rhythms in some blind subjects. J Clin Endocrinol Metab, 56, 1103–1107.
   Google Scholar
• Lindberger M, Tomson T, Ståhle L. (1998). Validation of microdialysis sampling for subcutaneous extracellular valproic acid in humans. Ther Drug Monit, 20, 358–362.
   PubMed Web of Science ®Google Scholar
• Mathy FX, Preat V, Verbeeck RK. (2001). Validation of subcutaneous microdialysis sampling for pharmacokinetic studies of flurbiprofen in the rat. J Pharm Sci, 90, 1897–1906.
   PubMed Web of Science ®Google Scholar
• Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D, Cruz-Sanchez F, Chyan YJ, Smith MA, Perry G, Shoji M, Abe K, Leone A, Grundke-Ikbal I, Wilson GL, Ghiso J, Williams C, Refolo LM, Pappolla MA, Chain DG, Neria E. (2003). Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer’s disease. J Neurochem, 85, 1101–1108.
   PubMed Web of Science ®Google Scholar
• Merkus P, Guchelaar HJ, Bosch DA, Merkus FW. (2003). Direct access of drugs to the human brain after intranasal drug administration? Neurology, 60, 1669–1671.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Yamaguchi H, Iwakura Y, Morisaka K, Ohashi Y, Nakai Y. (1991). Effects of viscous hyaluronate-sodium solutions on the nasal absorption of vasopressin and an analogue. Pharm Res, 8, 471–474.
   PubMed Web of Science ®Google Scholar
• Pappolla MA, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, Frangione B, Ghiso J. (1998). Inhibition of Alzheimer β-fibrillogenesis by melatonin. J Biol Chem, 273, 7185–7189.
   PubMed Web of Science ®Google Scholar
• Pappolla MA, Chyan YJ, Frangione BPB, Wilson G, Ghiso J, Reiter RJ. (2000). An assessment of the antioxidant and antiamyloidogenic properties of melatonin: implications for Alzheimer’s disease. J Neural Transm, 107, 203–231.
   PubMed Web of Science ®Google Scholar
• Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DLM, Reiter RJ, Efthimiopoulos S, Robakis NK. (1997). Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer’s amyloid peptide. J Neurosci, 17, 1683–1690.
   PubMed Web of Science ®Google Scholar
• Paul P, Lahaye C, Delagrange P, Nicolas JP, Canet E, Boutin JA. (1999). Characterization of 2-[125I]iodomelatonin binding sites in Syrian hamster peripheral organs. J Pharmacol Exp Ther, 290, 334–340.
   PubMed Web of Science ®Google Scholar
• Picout DR, Ross-Murphy SB. (2003). Rheology of biopolymer solutions and gels. ScientificWorldJournal, 3, 105–121.
   PubMedGoogle Scholar
• Priano L, Esposti D, Esposti R, Castagna G, De Medici C, Fraschini F, Gasco MR, Mauro A. (2007). Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. J Nanosci Nanotechnol, 7, 3596–3601.
   PubMed Web of Science ®Google Scholar
• Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Ii WHF, Craft S. (2008a). Intranasal insulin administration dose dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis, 13, 323–331.
   PubMed Web of Science ®Google Scholar
• Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S. (2008b). Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology, 70, 440–448.
   PubMed Web of Science ®Google Scholar
• Sánchez-Barceló EJ, Mediavilla MD, Tan DX, Reiter RJ. (2010). Clinical uses of melatonin: evaluation of human trials. Curr Med Chem, 17, 2070–2095.
   PubMed Web of Science ®Google Scholar
• Stenken JA, Lunte CE, Southard MZ, Ståhle L. (1997). Factors that influence microdialysis recovery. Comparison of experimental and theoretical microdialysis recoveries in rat liver. J Pharm Sci, 86, 958–966.
   PubMed Web of Science ®Google Scholar
• Vaka SR, Murthy SN. (2010). Enhancement of nose-brain delivery of therapeutic agents for treating neurodegenerative diseases using peppermint oil. Pharmazie, 65, 690–692.
   PubMed Web of Science ®Google Scholar
• van den Berg MP, Merkus P, Romeijn SG, Verhoef JC, Merkus FW. (2004). Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: studies in rats and comparison with a human study. Pharm Res, 21, 799–802.
   PubMed Web of Science ®Google Scholar
• Wang X. (2009). The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci Ther, 15, 345–357.
   PubMed Web of Science ®Google Scholar
• Wang Y, Aun R, Tse FL. (1998). Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. Biopharm Drug Dispos, 19, 571–575.
   PubMed Web of Science ®Google Scholar
• Yamada K, Hasegawa M, Kametani S, Ito S. (2007). Nose-to-brain delivery of TS-002, prostaglandin D2 analogue. J Drug Target, 15, 59–66.
   PubMed Web of Science ®Google Scholar
• Yeleswaram K, McLaughlin LG, Knipe JO, Schabdach D. (1997). Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. J Pineal Res, 22, 45–51.
   PubMed Web of Science ®Google Scholar